Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: Interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial Journal Article
| Authors: | Janjigian, Y. Y.; Kawazoe, A.; Bai, Y.; Xu, J.; Lonardi, S.; Metges, J. P.; Yanez, P.; Wyrwicz, L. S.; Shen, L.; Ostapenko, Y.; Bilici, M.; Chung, H. C.; Shitara, K.; Qin, S. K.; Van Cutsem, E.; Tabernero, J.; Li, K.; Shih, C. S.; Bhagia, P.; Rha, S. Y.; behalf of the KEYNOTE-811 Investigators |
| Article Title: | Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: Interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial |
| Journal Title: | Lancet |
| Volume: | 402 |
| Issue: | 10418 |
| ISSN: | 0140-6736 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2023-12-01 |
| Start Page: | 2197 |
| End Page: | 2208 |
| Language: | English |
| DOI: | 10.1016/s0140-6736(23)02033-0 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| PUBMED: | 37871604 |
| DOI/URL: | |
| Notes: | Accession Number: 174061450 -- Entry Date: In Process -- Revision Date: 20231220 -- Publication Type: Journal Article -- Journal Subset: Biomedical; Editorial Board Reviewed; Europe; Expert Peer Reviewed; Peer Reviewed; UK & Ireland -- NLM UID: 2985213R. -- Source: Cinahl |
